19 results about "Buffy coat" patented technology

A processing device includes a pump system, a valve system, a centrifuge, and a controller. A fluid flow circuit is mounted to the device to execute a procedure in which whole blood is processed into a red blood cell product, a plasma product, and a platelet concentrate product. The blood is first separated into red blood cells, buffy coat, and plasma using the centrifuge, with the red blood cells and plasma being removed from the centrifuge, while the buffy coat remains in the centrifuge. The fluid remaining in the centrifuge is circulated through the centrifuge to form a homogenous mixture. Once the mixture is formed, it is separated in the centrifuge into platelet concentrate and red blood cells. A platelet product is then collected by using whole blood or previously collected red blood cells to push the platelet concentrate from the centrifuge to a collection container.

The present invention discloses a method for separating components after centrifugation of blood cells, which belongs to the field of medical technology. It is achieved by utilizing the photosensitivity of the sensor and the difference in relative light absorption of each component after blood cell separation; after centrifugation, the blood cells are separated into a red blood cell layer, a buffy coat, and platelet-poor plasma. When each phase passes through the sensor, the relative light absorption characteristics of each phase are different, thereby accurately monitoring the blood layer. When each phase of the present invention passes through the sensor, the light absorption characteristics of the blood components are different, and accurate blood layer monitoring is performed based on this principle. The composition of the prepared product phase and subphase can be changed by changing the preset hematocrit. The sensor pipeline part that matches the sensor is a flat pipeline with a cross-section that is close to a large and flat rounded rectangle. It is made of a material with good light transmittance such as polycarbonate, so that light of different wavelengths emitted by the LED light emitter can pass through the flat pipeline vertically and be received by the light receiver.

1. Name of the design product: bracelet (blood cell separation sheet). 2. Use of the design product: the design product is a bracelet worn on the wrist, which activates health conditions naturally through physical therapy in a non-drug and non-chemical way. 3. Design points of the design product: in the combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view 1.

The utility model relates to a device for preparing platelet-rich plasma with less blood volume. The device comprises a preparation tube unit, an upper tube cover unit, an isolation unit and a lower tube cover unit, the platelet-rich plasma preparation device has the advantages that by changing the structure of the preparation tube unit, the platelet-rich plasma preparation device can be suitable for treatment of small animals or pets; the volume of blood contained in the preparation tube unit is reduced, so that the centrifugation time is shortened, and the risks of infection and blood coagulation are reduced; besides, after the blood is centrifugally separated, a lower tube cover unit is arranged and is in threaded connection with a preparation tube unit, so that the lower tube cover unit can be rotated to adjust the volume of a fourth cavity of the preparation tube unit, the buffy yellow layer by layer is positioned in a third cavity, and the plasma is completely positioned in a second cavity of the preparation tube unit; therefore, subsequent extraction by medical staff is facilitated.

The present invention provides a novel blood-derived growth-factor-containing composition. The present invention for solving the above problem is a method for preparing a growth-factor-containing composition from blood, the method comprising a step for separating platelet-rich plasma that does not contain a buffy coat component from the blood, and a step for adding citric acid and / or a salt thereof to the blood or a processed product thereof.

The present invention relates to a novel blood biomarker SH3PXD2B for diagnosing hepatitis B virus (HBV)-associated hepatocellular carcinoma and a use thereof. In order to identify a novel serum biomarker, transcriptome profiling including buffy coat WTS data was used to distinguish blood biomarkers specific to the caused of hepatocellular carcinoma Confirmation was made through validation using publicly available large-scale RNA-seq data, and qRT-PCR and AUC analyses were performed. Through this, it was confirmed that SH3PXD2B was upregulated exclusively in hepatitis B virus hepatocellular carcinoma in buffy coat transcripts, and qRT-PCR data demonstrated significant upregulation of SH3PXD2B in HBV-HCC. Therefore, SH3PXD2B is expected to be advantageously utilized as a blood biomarker for hepatitis B virus-associated hepatocellular carcinoma.

The present invention relates to an in vitro method for detecting human somatic mutations comprising the steps of: (i) providing a human sample, preferably a blood sample, more preferably a plasma sample, a serum sample or a buffy coat sample from a subject; (ii) preparing a first nucleic acid sequencing library from nucleic acids present in the sample; (iii) hybridizing one or more TAC oligonucleotides from a first pool of TAC oligonucleotides (TAC oligonucleotides-1) to the first library of nucleic acids, thereby isolating a first subset of library nucleic acid molecules; (iv) sequencing a first subset of the library nucleic acid molecules and comparing the determined sequences to human reference sequences, thereby creating a first set of presumed informative sequence variations (PISV1); (v) hybridizing one or more TAC oligonucleotides from a second smaller pool of TAC oligonucleotides (TAC oligonucleotide-2) comprising TAC oligonucleotides specific for nucleic acid molecules of the first set of inferred informative sequence variations with the first library of nucleic acid molecules, thereby isolating a second subset of library nucleic acid molecules; (vi) sequencing a second subset of the library nucleic acid molecules and comparing the determined sequences to human reference sequences, thereby creating a second set of presumed informative sequence variations (PISV2); (vii) analyzing the inferred informative sequence variation (PISV2), thereby detecting somatic mutations in the subject sample. Steps (i) to (iv) are referred to as step A. Steps (v) to (vii) are referred to as step B.

The invention provides a plasma matrix bone block and a preparation method and application thereof, and belongs to the technical field of biomedical materials. The preparation method comprises the following steps: obtaining a liquid plasma matrix and a buffy coat, placing the liquid plasma matrix and the buffy coat together with bone substitute material particles in a solid plasma matrix blood collection tube, carrying out rotary oscillation, and solidifying to obtain a plasma matrix bone block precursor; the plasma matrix bone block precursor is placed in a mold, a pressurizing gasket is placed at a sample inlet of the mold, the plasma matrix bone block precursor is compressed and shaped through centrifugation, and the plasma matrix bone block is obtained. Compared with a traditional plasma matrix bone block, the plasma matrix bone block provided by the invention is higher in mechanical strength and slower in degradation rate, and has more advantages in the aspect of promoting bone defect repair; and the preparation method is simple and has strong repeatability.

The invention discloses the in vitro use of a non-LTR RTE biomarker, such as LINE-1, to diagnose neurodegenerative diseases, particularly tauopathies. The diagnosis is based on identifying an increase in the number of LINE-1 copies in the biological fluids of an individual, and the difference in the number of copies of a non-LTR RTE, LINE-1, per ng of DNA in a biological sample, preferably a buffy coat, between healthy subjects (Control) and ill patients. The tauopathies are: Alzheimer's Disease (EA), Mild Cognitive Impairment (DCL), Progressive Supranuclear Palsy (PSP) / Corticobasal Syndrome (SCB) and Frontotemporal Dementia (DFT). The invention also relates to a kit comprising means for detecting the biomarker in a biological sample obtained from the individual and means for comparing the levels of the biomarker of interest in the sample with a control reference obtained from healthy individuals, and relates to an in vitro method for detecting a non-LTR RTE, such as LINE-1, in a biological sample.

A blood processing and / or manufacturing system includes a processing device and a fluid flow circuit selectively arranged on the processing device. The processing device is configured to interact with the fluid flow circuit to perform one or more blood separation procedures in which plasma is separated from whole blood. The system further includes an optical grading system arranged relative to a vessel of the fluid flow circuit containing the separated plasma, wherein the optical grading system is configured to determine a main wavelength of the plasma in the vessel and determine a red blood cell grade and / or a buffy coat platelet grade based on the main wavelength of the plasma.

The methods, systems, and compositions provided herein enable improved methods for detecting non-cancerous somatic mutations in subjects by measuring buffy coat somatic mutations to improve identification of samples with age-related somatic mutations.

The utility model belongs to the field of blood component separation, and particularly relates to a leukocyte-depleted blood bag combined bag. The blood bag connecting bag comprises a blood sampling bag, the top of the blood sampling bag is connected with a first transfer bag through a first transfer pipe, the top of the blood sampling bag is sequentially connected with a second transfer bag and a third transfer bag through a second transfer pipe, and a leukocyte-depleting filter is arranged on the first transfer pipe and located between the blood sampling bag and the first transfer bag. According to the application, the transfer tube is arranged at the top to realize the transfer of the plasma, the albuginea layer and the red blood cells, the plasma and the albuginea layer share one transfer tube and are transferred to the corresponding transfer bag for storage, the transfer tube corresponding to the red blood cells is provided with the leukocyte-depleting filter, the albuginea layer contains platelets, and subsequent component preparation of the platelets can be carried out; the red blood cells are transferred into the first transfer bag through the first transfer tube to be stored, so that blood platelets are effectively prepared and reserved, and blood components are prevented from being lost.

The invention relates to an in-vitro method of diagnosis, prognosis, treatment response control, response prediction, of a particular human disease comprising the steps of: • (i) with one or more human samples, selected from the group comprising, a blood sample from a subject, a plasma sample, a serum sample, a urine sample, or a buffy coat sample; • (ii) preparing a first and at least a second nucleic acid sequencing library from the nucleic acids present in said samples; • (iii) mixing the nucleic acid sequencing libraries which were prepared to create a first mixed nucleic acid sequencing library (MNAL), • (iv) hybridizing one or more TAC oligonucleotides from a first TAC oligonucleotide pool (TAC oligonucleotide-1) to said first mixed nucleic acid library (MNAL) thereby isolating a first subset of library nucleic acid molecules; • (v) sequencing said first subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a first group of putatively informative sequence variants (PISV 1); • (vi) hybridizing one or more TAC oligonucleotides from a second TAC oligonucleotide pool comprising TAC oligonucleotides (TAC oligonucleotide-2) which are specific for the nucleic acid molecules of said first group of putatively informative sequence variants, to said first library of nucleic acid molecules thereby isolating a second subset of library nucleic acid molecules; • (vii) sequencing said second subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a second group of putatively informative sequence variants (PISV2); • (viii) analyzing the putatively informative sequence variants (PISV2) thereby diagnosing, prognosing, controlling the response to a drug, for a particular human disease state.

The present invention relates to a novel blood biomarker CD70 for diagnosing non virus-related hepatocellular carcinoma and a use thereof. In order to find a biomarker for non virus-related hepatocellular carcinoma, buffy coats were isolated from the blood of normal individuals and patients with chronic hepatitis / liver cirrhosis / liver cancer of non virus-related origin, genes differentially expressed between normal individuals and non virus-related liver cancer were identified through whole transcriptome data sequencing and analysis of target proteomes, and the diagnostic power of the identified genes was measured. Through this, a blood biomarker CD70 specific to non virus-related liver cancer and having high accuracy was discovered. Therefore, CD70 is expected to be effectively utilized as a blood biomarker for non virus-related hepatocellular carcinoma.

The present invention relates to devices and methods for collecting liquid samples such as for removing a target liquid sample fraction from a larger liquid sample, e.g., from a biological sample. These devices and methods are particularly useful for rapidly and cost-effectively removing the buffy coat layer from an anticoagulated blood sample. These devices and methods have the advantage that the removal can be made on blood sample processed by ordinary centrifugation and do not require more complicated or costly processing techniques such as density gradient centrifugation.

The invention relates to an in-vitro method of detecting a somatic mutation in a human comprising the steps of, (i) using a human sample, preferably a blood sample from a subject, more preferably a plasma sample, a serum sample, or a buffy coat sample, (ii) preparing a first and at least a second nucleic acid sequencing library from the nucleic acids present in said samples; (iii) mixing the nucleic acid sequencing libraries which were prepared to create a first mixed nucleic acid sequencing library (MNAL); (iv) hybridizing one or more TAC oligonucleotides from a first TAC oligonucleotide pool (TAC oligonucleotide-1) to said first mixed nucleic acid library (MNAL) thereby isolating a first subset of library nucleic acid molecules; (v) sequencing said first subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a first group of putatively informative sequence variants (PISV1), (vi) hybridizing one or more TAC oligonucleotides from a second TAC oligonucleotide pool comprising TAC oligonucleotides (TAC oligonucleotide 2) which are specific for the nucleic acid molecules of said first group of putatively informative sequence variants, to said first library of nucleic acid molecules thereby isolating a second subset of library nucleic acid molecules, (vii)sequencing said second subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a second group of putatively informative sequence variants (PISV2), (viii) analyzing the putatively informative sequence variants (PISV2) thereby detecting a somatic mutation in the sample from the subject. Steps (i) to (v) are referred to together as step A. Steps (vi) to (viii) are referred to together as step B.

The methods, systems, and compositions provided herein allow improved methods for detecting non-cancer somatic mutations in a subject by measuring buffy coat somatic mutations in order to improve identification of samples with age related somatic mutations.

The present invention relates to an in vitro method of diagnosis, prognosis, therapeutic response control, response prediction of a specific human disease, comprising the steps of: (i) providing a human sample, preferably a blood sample, more preferably a plasma sample, or a serum sample or buffy coat sample from a subject; (ii) preparing a first nucleic acid sequencing library from nucleic acids present in the sample; (iii) hybridizing one or more TAC oligonucleotides from a first library of TAC oligonucleotides (TAC oligonucleotide-1) to the first library of nucleic acids, thereby isolating a subset of first library nucleic acid molecules; (iv) sequencing the first subset of library nucleic acid molecules and comparing the determined sequences to human reference sequences, thereby creating a first set of presumption information sequence variants (PISV 1); (v) hybridizing one or more TAC oligonucleotides from a second bank of smaller TAC oligonucleotides comprising TAC oligonucleotides (TAC oligonucleotides-2) specific for nucleic acid molecules of the first set of inferred information sequence variants to the first library of nucleic acid molecules, thereby isolating a subset of second library nucleic acid molecules; (vi) sequencing the second subset of library nucleic acid molecules and comparing the determined sequences to human reference sequences, thereby creating a second set of inferred information sequence variants (PISV2); (vii) analysing the inferred information sequence variants (PISV2) to diagnose, prognose, and control the response to the drug against a specific human disease state. Steps (i) to (iv) are also collectively referred to as step A. Step (v) to (vii) are also collectively referred to as Step B.

A method for detecting cancer susceptibility, early detection and predicting cancer behaviour by using specific markers and parameters described below: screening persons with high risk of getting / having a type of cancer; identifying CNV / SNP / MNP / Indel loci and / or CNV / SNP / MNP / Indel mutations specific to a cancer / cancer stage and common in the buffy coat and tumor of cancer patients / stage of cancer; predicting mutations that will occur when metastasis or recurrence of cancer / tumor occurs by identifying CNV / Indel / SNP / MNP loci and / or Indel / SNP / CNV / MNP mutations in buffy coat and tumor by analysis of defined and timed samples of buffy coat, primary, secondary / recurrent tumor; determining loci and mutations indicative of the tumor behaviour, selected from responsiveness to treatment, toxicity of therapies, dose optimization, minimal residual disease; indicative of progression of disease, timing of recurrence and determining pathways responsible for various behaviours.